The story of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial introduction generated substantial gains, the lapse of its intellectual property protection opened the door to off-brand versions, dramatically reducing market share. This poses a unique challenge for firms relying on simila

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly eroding its dominance. While certain firms may seek to capitalize on male sexual dysfunction, the existing land